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Abstract
Objective: Early-onset colorectal cancer (CRC) represents a clinically distinct form of CRC that is often associated with a poor
prognosis. Methylation levels of genomic repeats such as LINE-1 elements have been recognized as independent factors for
increased cancer-related mortality. The methylation status of LINE-1 elements in early-onset CRC has not been analyzed
previously.
Design: We analyzed 343 CRC tissues and 32 normal colonic mucosa samples, including 2 independent cohorts of CRC
diagnosed #50 years old (n = 188), a group of sporadic CRC .50 years (MSS n = 89; MSI n = 46), and a group of Lynch
syndrome CRCs (n = 20). Tumor mismatch repair protein expression, microsatellite instability status, LINE-1 and MLH1
methylation, somatic BRAF V600E mutation, and germline MUTYH mutations were evaluated.
Results: Mean LINE-1 methylation levels (6SD) in the five study groups were early-onset CRC, 56.6% (8.6); sporadic MSI,
67.1% (5.5); sporadic MSS, 65.1% (6.3); Lynch syndrome, 66.3% (4.5) and normal mucosa, 76.5% (1.5). Early-onset CRC had
significantly lower LINE-1 methylation than any other group (p,0.0001). Compared to patients with ,65% LINE-1
methylation in tumors, those with $65% LINE-1 methylation had significantly better overall survival (p = 0.026, log rank
test).
Conclusions: LINE-1 hypomethylation constitutes a potentially important feature of early-onset CRC, and suggests a distinct
molecular subtype. Further studies are needed to assess the potential of LINE-1 methylation status as a prognostic
biomarker for young people with CRC.
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Introduction
Colorectal cancer (CRC) is an important public health problem
and represents the second most frequent cancer and the second
greatest cause cancer-related mortality in most of the developed
world. Each year, one million people develop CRC, and 40–50%
of them will die within 5 years of diagnosis [1]. CRCs are highly
heterogeneous both histopathologically, and at the molecular and
genetic level. It appears that the biology and response to therapies
is equally diverse. Understanding the molecular mechanisms of
colorectal carcinogenesis is essential for the development of new
strategies for prevention, diagnosis, treatment and prognosis.
Although CRC has been a major focus of attention for basic and
clinical research during the last 25 years, we still lack robust
biomarkers that can be used for diagnosis and treatment of CRC.
The peak incidence of CRC is between 60–70 years old;
however up to 10% of all cases occur before age 50. Moreover,
recent epidemiological studies suggest that the incidence of early-
onset CRC is increasing, representing an important clinical
challenge [2]. Early-onset CRC often presents with advanced
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stage tumors, which contributes to a higher rate of mortality [3].
Since young people are not included in CRC screening programs,
there is an urgent need to understand the biology of early-onset
tumors, which could facilitate earlier detection and treatment of
these cancers.
Although early-onset CRC raises the possibility of a hereditary
risk factor, the known non-polyposis hereditary CRC syndromes
(Lynch Syndrome and MUTYH-associated CRC) represents no
more than 15–20% of cases in this group [4,5,6]. Lynch Syndrome
accounts for about 3% of all CRC cases, and is caused by germline
mutations of the DNA mismatch repair (MMR) genes (MLH1,
MSH2, MSH6 and PMS2) [7]. It is characterized by early-onset
cancers arising in the colorectum and other organs, and there are
currently several strategies and algorithms to predict the presence
of a germline mutation in one of the MMR genes [8,9,10,11].
Biallelic mutations in the MUTYH gene (a member of the base
excision repair system) accounts for,1% of all CRC, and usually
causes an attenuated form of polyposis, although 30% of these
patients can manifest as a non-polyposis CRC [12].Identifying
individuals with germline mutations that predispose to CRC has
significant implications for the clinical management of affected
individuals and for their relatives.
The remaining 75–80% of early-onset CRC represents another
group in which the genetic etiology has not yet been discovered. In
contrast to CRC on older individuals, early-onset CRC is often
characterized by more advanced stage, distal location (especially in
rectum), mucinous and poorly differentiated tumors with signet
ring cells, and a poorer prognosis [4,13,14]. The majority of these
cancers do not show microsatellite instability (MSI), but rather are
microsatellite stable (MSS). The molecular basis for the biological
and behavioral differences in early-onset CRC is unclear.
Genome-wide DNA hypomethylation is a frequent epigenetic
alteration that is an early event in CRC and has been associated
with the activation of certain proto-oncogenes (i.e. MET) [15] and
the presence of chromosomal instability [16,17]. Global DNA
hypomethylation can be measured indirectly by assessing the
methylation status of long interspersed nucleotide element-1
(LINE-1) repeat sequences [18]. The pyrosequencing assay for
LINE-1 methylation has been found to be quantitative, robust and
reproducible [19]. The degree of LINE-1 hypomethylation has
been recognized as an independent factor for increased cancer-
related mortality and overall mortality in CRC patients [20].
Although it has been suggested that LINE-1 hypomethylation is
associated with CRC in younger patients [21], the specific
association between methylation status of LINE-1 elements and
early-onset CRC has not been further analyzed.
The aim of this study was to characterize the clinical,
histological, and molecular features of a large cohort of early-
onset CRCs in the context of the methylation status of LINE-1
elements. Our results indicate that LINE-1 hypomethylation in
these tumors constitutes a unique and specific feature, which is
suggestive of a distinct molecular subtype in these colorectal
neoplasms. Our findings suggest that LINE-1 methylation status




The study was approved by the Institutional Review Boards
(IRB) of each participating center, including Hospital of Gastro-
enterology ‘‘Dr. C. B. Udaondo’’, Buenos Aires, Argentina, Baylor
University Medical Center, Dallas, TX and the Epicolon
consortium. A written informed consent was obtained from all
patients.
Patients
We analyzed 343 CRCs from different clinic-pathological
groups, and 32 normal colonic mucosa samples. We included a
cohort of 118 retrospectively recruited CRC patients #50 years
old seen at the Oncology Section of the Argentine Public Hospital
of Gastroenterology between 1993 and 2009. Patients with
colorectal polyposis or inflammatory bowel disease were excluded.
Demographic and clinic-pathological features were collected from
each patient’s medical history, and family history of cancer in first
and second degree relatives was obtained by personal interview.
The median follow-up time was 39 months (range, 1.5–195
months). For the LINE-1 methylation analyses, as a validation
group, we included a previously described cohort of 70 patients
with CRC diagnosed #50 years old treated at two Spanish centers
(Hospital Clinic of Barcelona and Hospital of Donostia) between
1995–2007 [4]. We also included a population-based cohort of
sporadic CRCs.50 years recruited in Spain (Epicolon I study) [9]
categorized by the presence of MSI (‘‘sporadic MSI’’ due to
somatic MLH1 promoter hypermethylation [n = 46], and ‘‘spo-
radic MSS’’ [n = 89]); and a group of Lynch syndrome CRCs
recruited at Baylor University Medical Center at Dallas (n = 20).
We histologically analyzed normal colonic mucosa from 32
individuals undergoing colonic surgery for reasons other than
cancer (i.e. diverticulosis) recruited in the Hospital Clinic of
Barcelona, Spain.
DNA Isolation
Genomic DNA from each patient were extracted from
formalin-fixed paraffin-embedded (FFPE) microdissected tumor
tissues using the QiaAmp Tissue Kit (Qiagen, Courtaboeuf,
France) according to the manufacturers’ instructions. Peripheral
blood DNA was extracted using the QiaAmpDNA blood Mini Kit
(Qiagen, Courtaboeuf, France). For rectal tumors in which chemo-
radiotherapy was administered, pre-treatment tissue samples were
analyzed.
Tumor Mismatch Repair Protein Expression
One block of FFPE tumor tissue was selected per case and
immunostaining was performed using standard protocols. The
following mouse monoclonal antibodies were used: anti-MLH1
(clone G168-728, diluted 1:250, PharMingen, San Diego, CA),
anti-MSH2 (clone FE11, diluted 1:50, Oncogene ResearchPro-
ducts, Cambridge, MA), anti-MSH6(clone GRBP.P1/2.D4, dilut-
ed 1:200; Serotec Inc, Raleigh, NC) and anti-PMS2 (clone A16-4,
diluted 1:200, BD PharMingen, San Diego, CA). A tumor was
deemed negative for protein expression only if the neoplastic
epithelium lacked nuclear staining, while non-neoplastic epithelial
or stromal cells retained normal expression of that protein.
Tumor Microsatellite Instability Analysis
MSI analysis was carried out using five mononucleotide repeat
microsatellite targets (BAT-25, BAT-26, NR-21, NR-24 and NR-
27) in a pentaplex PCR system. Primer sequences have been
described previously [22]. Tumors with instability at $3 these
markers were classified as microsatellite unstable (MSI) and those
showing instability at #2 markers as microsatellite stable (MSS).
The researchers scoring immunostaining were blinded to the MSI
results, and vice versa.
LINE-1 Hypomethylation in Early-Onset CRC
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Methylation Analyses
DNA was modified with sodium-bisulfite using the EZ
Methylation Gold Kit (Zymo Research, Orange, CA). Methyla-
tion of LINE-1 sequences and the promoter of MLH1 was
analyzed by quantitative bisulfite pyrosequencing as described
previously [23]. Primers are detailed in Table S1.
Germline MUTYH Gene Mutation Analysis
All patients were screened for the two most prevalent MUTYH
mutations in Caucasian populations (p.G393D and p.Y176C) by
pyrosequencing. Primers are detailed in Table S1. In heterozy-
gotes for any of these mutations, the coding region and exon-
intron boundaries of the MUTYH gene were screened by SSCP
with sequencing of abnormal band shifts, as described previously
[12].
Somatic BRAF V600Emutation Analysis
The BRAF V600E mutational analysis was performed by
pyrosequencing. The PCR and sequencing primers are detailed
in Table S1.
Statistical Analysis
Quantitative variables were compared using Student’s test.
Qualitative variables were compared using either the Chi Square
or the Fisher’s test when appropriate. For associations with MMR
deficiency and LINE-1 methylation (treated as a binary variable) a
multivariate analysis using a stepwise backward logistic regression
procedure was performed to assess the independent associations.
The Mann Whitney test was used to compare LINE-1 values.
Overall survival associated with clinic-pathological and molecular
variables (tumor stage, MMR deficiency, tumor location, family
history of CRC, tumor differentiation, mucinous component,
tumor infiltrating lymphocytes and LINE-1 methylation) were
calculated by the Kaplan–Meier method (log rank test). A two
sided p-value of ,0.05 was regarded as significant. SPSS v17
software was used for statistical analysis.
Results
Patient’s Characteristics
We recruited 118 patients with early-onset CRC. Clinico-
pathological features are shown in Table 1. The mean age at
diagnosis was 37 years (standard deviation (SD), 8.25), and 61
(51.7%) patients were female. In 34 (28.8%) the tumor was
proximal to the splenic flexure, 35 (29.6%) were in the distal colon,
and 49 (41.6%) were in the rectum. At presentation, 22 (18.6%)
patients had 1–10 synchronous adenomas; 18 presented with 1–5
adenomas and 4 patients had 6–10 adenomas. Three cases (2.5%)
had a synchronous tumor (2 CRC and 1 neuroendocrine tumor in
the appendix), and 5 (4.2%) developed a metachronous tumor
during follow-up (4 CRC and 1 urothelial carcinoma). The
majority of cases (77; 65.3%) were diagnosed at advanced stages
(III-IV). Poorly differentiated tumors were seen in 15 (13.1%)
patients, 41 (34.7%) had mucinous features and 65 (55%) had
pathological features suggestive of the MSI phenotype, with one or
more of the following: signet ring cells, Crohn’s-like lymphocytic
reaction, tumor infiltrating lymphocytes, medullary growth
pattern, or anaplastic features. More than 85% (n = 100) of the
patients had experienced abdominal pain prior to diagnosis, 83
(70%) presented with an alteration in bowel habits, 71 (60%) had
rectal bleeding and weight loss, 34 (29%) had iron deficiency
anemia, 18 (15.5%) presented with bowel obstruction, and 6 (5%)
with perforation. The average delay between initial symptoms and
CRC diagnosis was 6.565 months. Fifteen patients (12.7%) had a
family history of CRC or another Lynch syndrome-associated
neoplasm in first or second-degree relatives. Three patients met
Amsterdam I criteria, 3 patients met Amsterdam II criteria, 4
patients had one first degree relative with CRC, 3 patients had two
or more second degree relatives with CRC, and 2 patients had one
second degree relative with CRC.
Germline MUTYH Gene Mutation Analysis
Biallelic MUTYH mutations were found in 1/91 MMR-
proficient cases (1.1%)(Table S2). This single case was a 29-
year-old patient with a stage III rectal cancer and 2 synchronous
adenomas. Two siblings of this patient had a history of attenuated
polyposis and CRC (one presented with 30 adenomas and the
other with 8 adenomas and an in situ carcinoma in the cecum); in
both siblings total colectomies had been performed. Finally, we
identified two p.G393D heterozygous patients that had no specific
clinico-pathological features (Table S2).
Mismatch Repair Deficiency Analysis
MMR deficiency was evaluated by MSI analysis and immuno-
histochemistry, and was defined by the presence of MSI in a
tumor, and/or loss of expression in any of the MMR proteins.
Twenty seven (22.9%) tumors were classified as MMR deficient,
and 25 of these showed loss of protein expression (8 for MLH1/
PMS2, 1 for isolated MLH1, 4 for isolated PMS2, 11 for MSH2/
MSH6, and 1 for isolated MSH6). Clinico-pathological features of
patients with MMR deficiency are summarized in Table 2.
Nearly all cases of MSI had loss of protein expression; two cases
with MSI retained normal expression of all four proteins. Likewise,
1 case with loss of MSH6 expression and one case with loss of
PMS2 were MSS. The last patient was a 24 year-old woman who
had CRC at age 15, a urothelial carcinoma at age 23, a
metachronous CRC at age 24, and finally, a mediastinal B-cell
lymphoma. Her CRC specimen showed loss of expression of
PMS2 in tumor cells and in normal colonic surrounding tissue,
leading to a presumptive diagnosis of constitutional MMR-
deficiency syndrome due to bi-allelic PMS2 mutations.
As shown in Table 1, compared to MMR-proficient tumors,
MMR-deficient tumors were more likely to be located in the
proximal colon (59.3% vs. 19.8%, p = 0.0001), to be mucinous
(63% vs. 26.4%, p = 0.0001), to have tumor infiltrating lympho-
cytes (59.3% vs. 11.5%, p = 0.0001), and to have MSI-suggestive
pathology (81.5% vs. 47.2%, p = 0.002). MMR deficient tumors
were also more likely to be diagnosed at a lower stage (stages I–II:
51.9% vs. 29.7%, p = 0.03), and to have less tumor recurrence or
progression (22.2% vs. 44%, p = 0.042). Multivariate analysis
showed that independent variables associated with MMR
deficiency were: proximal location (OR = 3.86 [95%CI: 1.32–
11.32]; p = 0.013), mucinous features (OR = 3.38 [95%CI: 1.16–
9.84]; p = 0.025) and presence of tumor infiltrating lymphocytes
(OR = 8.8 [95%CI: 2.93–26.31]; p = 0.0001). Although there was
no difference in the age of CRC diagnosis between the 2 groups,
the chance of having a MMR-deficient tumor was greater among
younger patients (12–30 years: 8/27, 29.6%; 31–40 years: 9/45,
20%, 41–50 years: 10/46, 21.7%).
Somatic BRAF mutation was present in one MMR-deficient
tumor (Table 2). This case was a 49-year-old male with an MSI
tumor in the cecum that showed loss of MLH1 and PMS2 protein
expression. This case showed high degree of MLH1 promoter
methylation (88%) and was therefore likely associated with CpG
island methylator phenotype (CIMP) [24]. In the rest of theMLH1-
deficient tumors, presumably carriers of MLH1 germline muta-
tions, 4 showed very low levels of methylation (range, 1–2%), and
the other 4 showed intermediate levels (range, 25–51%).
LINE-1 Hypomethylation in Early-Onset CRC
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Table 1. Clinical, pathological and molecular features of patients with mismatch repair deficiency.
Clinical, pathological or molecular feature Cohort N = 118
MMR deficient1
N = 27 (22.9%)
MMR proficient2
N = 91 (77.1%) p-value
Age at diagnosis, mean (standard deviation) 37 (8.25) 35 (10.06) 38 (7.55) 0.23
Age range (29–45) (25–45) (30–45)
Sex, n (%)
Female 61 (51.7) 13 (48.1) 48 (52.7) 0.67
Male 57 (48.3) 14 (51.9) 43 (47.3)
Tumor location, n (%)
Rectum 49 (41.5) 6 (22.2) 43 (47.3) 0.0001
Distal to splenic flexure 35 (29.7) 5 (18.5) 30 (33)
Proximal to splenic flexure 34 (28.8) 16 (59.3) 18 (19.8)
Synchronous or metachronous CRC, n (%)
Yes 6 (5.1) 3 (11.1) 3 (3.3) 0.132
No 112 (94.9) 24 (88.9) 96.7)
Synchronous adenomas, n (%)
0 81 (68.6) 18 (66.7) 63 (69.2) 0.589
1–5 18 (15.2) 6 (22.2) 12 (13.2)
6–10 4 (3.4) 1 (3.7) 3 (3.3)
Incomplete colonoscopy 15 (12.8) 2 (7.4) 13 (14.3)
Synchronous hyperplastic polyps, n (%)
0 95 (80.5) 24 (86.2) 71 (78.0) 0.644
1–5 7 (6) 1 (6.9) 6 (6.6)
6–10 1 (0.70) 0 (0) 1 (1.1)
Incomplete colonoscopy 15 (12.8) 2 (6.9) 13 (14.3)
Family history of CRC or other Lynch syndrome associated neoplasia3, n (%)
Yes 15 (12.7) 5 (18.5) 10 (11.0) 0.30
No 103 (87.3) 22 (81.5) 81 (89.0)
TNM tumor stage, n (%)
I–II 41 (34.7) 14 (51.9) 27 (29.7) 0.03
III–IV 77 (65.3) 13 (48.1) 64 (70.3)
Tumor differentiation, n (%)
Well or moderate 100 (86.9) 24 (88.9) 76 (86.3) 1
Poor 15 (13.1) 3 (11.1) 12 (13.7)
Mucinous component, n (%)
.50% 41 (34.7) 17 (63) 24 (26.4) 0.0001
,50% 77 (65.3) 10 (37) 67 (73.6)
Tumor infiltrating lymphocytes, n (%)
Yes 26 (22.8) 16 (59.3) 10 (11.5) 0.0001
No 88 (77.2) 11 (40.7) 77 (88.5)
Medullary growth pattern, n (%)
Yes 11 (9.4) 3 (11.1) 8 (8.9) 0.714
No 106 (90.6) 24 (88.9) 82 (91.1)
Tumors withCrohns reaction, n (%)
Yes 12 (10.6) 5 (18.5) 7 (8.1) 0.154
No 101 (89.4) 22 (81.5) 79 (91.9)
Pathology suggestive of MSI4, n (%)
Yes 65 (55) 22 (81.5) 43 (47.2) 0.002
No 53 (45) 5 (18.5) 48 (52.8)
Somatic BRAF mutations, n (%)
Wild-type 108 (96.4) 25 (96.2) 83 (96.5) 1
Mutated 4 (3.6) 1 (3.8) 3 (3.5)
LINE-1 Hypomethylation in Early-Onset CRC
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LINE-1 Methylation Analysis
We used the quantitative bisulfite pyrosequencing method to
determine the methylation status of LINE-1 repetitive sequences in
the CRCs. The average methylation in the CRCs was 59.97%
(standard deviation, 6.57), which followed a normal distribution
(Figure S1). Clinico-pathological features associated with LINE-1
methylation are shown in Table 3. A significant difference in
LINE-1 methylation status was found according to tumor location,
with lower levels of methylation in distal compared with proximal
tumors (59.02% vs. 62.3%, p = 0.015). In addition, a trend towards
lower levels of methylation was found in females (58.87% vs. 60.93,
p = 0.092) and in non-mucinous tumors (59.24% vs. 61.41%,
p = 0.096). No differences in LINE-1 methylation status were
found for any of the other clinic-pathological features.
We then compared the LINE-1 methylation levels in this series
with another independent cohort of patients with CRC diagnosed
at ,50 years of age recruited in Spain [4], 2 groups of patients
with sporadic CRC diagnosed .50 year-old categorized by the
presence or absence of MSI (MSI, n = 46; mean age: 70.2+13.9
years old; and MSS, n = 89; mean age: 70.6611.4 years old), a
group of Lynch Syndrome CRCs (n = 20), and normal colonic
mucosa from individuals without tumors (n = 32) (Figure 1 and
Table 4). Clinico-pathological features of both cohorts of early-
onset CRCs are depicted in Table S3. Both cohorts were similar
in terms of tumor location and tumor pathological features. As
expected, the average LINE-1 methylation levels in normal
colonic mucosa were higher than in tumor tissues for all groups.
LINE-1 methylation levels in early-onset CRCs was 59.9% (SD,
6.5) and 51.1% (SD, 9.2) for the Argentinian and the Spanish
cohorts, respectively. The mean methylation level in the combined
cohort of early-onset CRCs (n = 185) was 56.6% (SD, 8.6).
Interestingly, tumor LINE-1 methylation levels in the two
independent cohorts of early-onset CRC were significantly lower
than that observed in older-onset CRCs and Lynch syndrome
tumors (Table 4), suggesting that this represents a unique feature
of this subgroup of tumors (p,0.0001 for all comparisons). LINE-
1 hypomethylation levels were similar in older-onset sporadic MSI
tumors (67.1%, SD 5.5), Lynch syndrome CRCs (66.3%, SD 4.5),
and sporadic MSS tumors (65.1%, SD 6.3).
Survival Analyses
Follow-up was available on all 118 patients, ranging from 1.5 to
195 months, with a mean of 39 months. The 3-year survival rate
for all 118 patient in this series was 84.7%; 46 patients (39%)
relapsed or had progression of disease, 22 (18.6%) died, and 3
patients were lost to follow-up. Advanced tumor stage was
significantly associated with a worse 3-year overall survival (stages
I-II: 92.9% vs. stages III-IV: 82.9%;p = 0.046, log rank test) and a
trend was observed for better survival in patients with mucinous
tumors (95.1% vs. 82.9%; p = 0.077, log rank test) or with tumor
infiltrating lymphocytes (96.2% vs. 85.2%; p = 0.16, respectively;
log rank test). Patients with MMR-deficient tumors showed a trend
towards a better 3-year overall survival (96.3% vs. 83.5%; p = 0.1,
log rank).
Next, we evaluated the effect of LINE-1 hypomethylation on
the overall survival of CRC patients. With the aim of identifying a
cut-off value of LINE-1 that could distinguish a group of patients
with worse prognosis, several cut-offs starting from the lowest level
of LINE-1 methylation were evaluated. We found that in
comparison to patients with ,65% LINE-1 methylation, those
with $65% LINE-1 methylation had significantly better overall
survival (83.5% vs. 100%; p = 0.026, log rank test; p = 0.039,
Fisher’s exact test; Figure 2). Comparison of clinico-patological
and molecular features of patients according to the level of LINE-1
methylation is shown in Table 5. Interestingly, tumors with
LINE-1 methylation $65% were more frequently mucinous
(60.9% vs 24.5%, p = 0.003) and those patients had higher
frequency of synchronous or metachronous tumors (13% vs 2.2%,
p = 0.054). Multivariate analysis showed mucinous tumors as the
only variable associated with tumor with LINE-1$65%
(OR = 4.32 (95%CI: 1.65–11.34); p = 0.003), independently of
the MMR deficiency status.
Discussion
Several studies have suggested that early-onset CRC constitutes
a biologically distinct disease that is frequently associated with
advanced stage, distal tumors, and poor prognosis. We and others
have shown that the known hereditary cancer syndromes only
explain a minority of early-onset CRC cases [2,4,5,13]; conse-
quently, the pathogenic mechanism in the majority of cases
remains unknown. In this study we aimed to gain further insight
into the pathogenesis of early-onset CRC by assessing the clinic-
pathological and molecular features of 118 patients with early-
onset CRC. The most interesting and novel result we observed is
that LINE-1 hypomethylation constitutes a unique feature of
early-onset CRC patients. LINE-1 hypomethylation is a surrogate
marker for genome-wide hypomethylation and is associated with
increased chromosomal instability [16,17]; therefore, this finding
may help explain some of the biological mechanisms underlying
early-onset CRC. In addition, we found that the frequency of
Table 1. Cont.
Clinical, pathological or molecular feature Cohort N = 118
MMR deficient1
N = 27 (22.9%)
MMR proficient2
N = 91 (77.1%) p-value
LINE-1 methylation, mean (standard deviation) 59.97 (6.57) 61.26 (6.13) 59.7 (6.68) 0.244
Progression/recurrence
Yes 46 (39) 6 (22.2) 40 (44) 0.042
No 72 (61) 21 (77.8) 51 (56)
Three-year overall survival 84.7%% 96.3% 83.5% 0.115
1MSI-H and/or loss of expression of MMR proteins by immunohistochemistry.
2MSS and normal expression of MMR proteins by immunohistochemistry.
3Including first and second degree relatives; Lynch syndrome-associated neoplasia includes: endometrium, stomach, ovaries, urinary tract, small intestine, pancreas, bile
ducts, brain or sebaceous glands.
4Signet ring cells and/or Crohn’s-like lymphocytic reaction and/or tumor infiltrating lymphocytes and/or medullary growth pattern and/or anaplastic tumor.
doi:10.1371/journal.pone.0045357.t001
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Table 3. LINE-1 methylation level in early-onset colorectal cancer.
Clinical, pathological or molecular features Total (n)* Mean Standard deviation p-value
Sex
Male 61 60.93 6.598 0.092
Female 54 58.87 6.422
Age
.30 years 91 60.26 6.757 0.345
,30 years 24 58.83 5.791
Body Mass Index (kg/m2)
,30 100 59.71 6.029 0.728
.30 10 60.4 5.337
Family history of CRC1
Yes 16 59.68 6.005 0.246
No 99 61.75 9.40
Tumor location
Rectum 47 58.3 6.54 0.026
Distal to splenic flexure 35 60 5.46
Proximal to splenic flexure 33 62.3 7.12
Synchronous or metachronous CRC
Yes 5 64.2 6.76 0.141
No 110 59.77 6.52
TNM tumor stage
I–II 40 59.63 6.054 0.687
III–IV 75 60.15 6.861
Tumor differentiation
Well or moderate 97 60.03 6.555 0.926
Poor 15 60.2 6.527
Mucinous component
.50% 39 61.41 5.959 0.096
,50% 75 59.24 6.824
Medullary growth pattern
Yes 11 61.36 4.905 0.453
No 103 59.79 6.748
Crohns reaction
Yes 12 62.75 3.545 0.128
No 98 59.63 6.908
Tumor infiltrating lymphocytes
Yes 26 60.88 5.443 0.447
No 85 59.74 7.004
Microsatellite instability
MSI 25 59.72 6.717 0.454
MSS 90 60.84 6.053
Mismatch repair deficiency2
Yes 27 61.26 6.137 0.244
No 88 59.7 6.680
P value was calculated by t-test.
*Referred to patients with available information.
1Including first and second degree relatives.
2MSI-H and/or loss of expression of MMR proteins by immunohistochemistry.
doi:10.1371/journal.pone.0045357.t003
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MMR deficiency in this cohort is ,20%, which is consistent with
previous reports that characterized such populations [4,5,6].
Finally, we found that MUTYH deficiency accounts for ,1% of
MMR-proficient CRCs. This work and the previous work help
exclude a number of possible explanations for early-onset CRC.
Cancer is a complex disease, which arises as a result of both
genetic and epigenetic alterations. Human CRCs often display
changes in DNA methylation, and it has been known for decades
that genome-wide hypomethylation is a consistent biochemical
characteristic of human colorectal tumors [16,17,25]. In mice,
DNA hypomethylation is sufficient to induce T cell lymphomas
[26]. Genome-wide hypomethylation plays a causative role in
cancer through different mechanisms: genomic instability, tran-
scriptional activation of proto-oncogenes, activation of endoge-
nous retroviruses and transposable elements, and the induction of
inflammatory mediators. All these mechanisms have been
Figure 1. LINE-1 methylation analysis by bisulfite pyrosequencing in different CRC subsets. Bisulfite pyrosequencing of LINE-1 in
colorectal tissues; Normal mucosa (n = 32), early-onset CRC from Argentina (n = 116), early-onset CRC from Spain (n = 70), older onset CRC with
microsatellite stability (MSS; n = 89), older onset CRC with microsatellite instability (MSI) associated with MLH1 promoter hypermethylation (n = 46)
and Lynch syndrome CRCs (n = 20).The black horizontal bar indicates the mean methylation level.
doi:10.1371/journal.pone.0045357.g001
Table 4. LINE-1 methylation results in different clinical subgroups.
Mean % LINE-1 methylation (SD) Range p-value1 p-value2
Normal colonic mucosa (n = 32) 76.5 (1.5) 73.5–80.2
Earlyonset CRC (n = 185) 56.6 (8.6) 22–82 ,0.0001
Lynch syndrome CRC (n = 20) 66.3 (4.5) 52.1–73.1 ,0.0001 ,0.0001
Older onset sporadic MSI (n = 46) 67.1 (5.5) 44.7–78.3 ,0.0001 ,0.0001
Older onset sporadic MSS (n = 89) 65.1 (6.3) 42.5–78.4 ,0.0001 ,0.0001
CRC, colorectal cancer; SD, standard deviation.
Mann Whitney test was used to compare the LINE-1 values.
1Values for comparison between normal colonic mucosa and other groups of CRC.
2Values for comparison between early onset CRC (n = 185) and other groups of CRC.
doi:10.1371/journal.pone.0045357.t004
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associated with DNA hypomethylation, poor prognosis and tumor
aggressiveness [26,27,28,29,30,31]. Repetitive nucleotide ele-
ments, including long interspersed nucleotide elements-1 (i.e.,
LINE-1) contain numerous CpG sites, and prior studies have
established that the level of LINE-1 methylation is an accurate
indicator of cellular 5-methylcytosine content [18], which reflects
global DNA methylation. In recent years, it has been suggested
that LINE-1 methylation may identify different molecular
subtypes of CRC. CIMP and MSI are inversely associated with
DNA hypomethylation, suggesting that genomic hypomethylation
represents an alternative pathway for CRC progression, and may
reflect a fundamentally different disease process [32,33]. More-
over, LINE-1 hypomethylation has been associated with poorer
survival among patients with CRC, and represents an independent
factor for increased cancer-related mortality and overall mortality
[20]. Therefore, evaluation of tumoral LINE-1 methylation and its
correlation with clinical and pathological features is important to
determine the potential clinical value of this biomarker.
We used a quantitative pyrosequencing assay for LINE-1
methylation, which is a robust, accurate and reproducible method
to precisely quantitate this in individual tumors [18]. Compared to
older-onset colorectal tumors, we found significantly lower levels of
LINE-1 methylation in early-onset CRCs. This observation was
validated in an independent set of early-onset CRC patients,
reinforcing the strength of our conclusions. In addition, we found
that LINE-1 hypomethylation was associated with distal tumors
and worse prognosis. Although there are no previous studies that
have specifically examined LINE-1 methylation in early-onset
CRC patients, a recent study suggested a relationship between
greater LINE-1 hypomethylation in CRC and earlier onset of the
cancer (,60 years) [21]. Overall these findings suggest the
presence of a distinct subtype of CRC with a unique pathogenic
mechanism [4,13]. Since the degree of LINE-1 hypomethylation is
a prognostic marker in CRC and our data show that LINE-1
hypomethylation is a characteristic feature of early-onset CRC,
this study provides a novel and previously unrecognized explana-
tion for some of the biological differences (tumor location,
prognosis and pathological features) involved in early-onset CRCs.
These results provide an opportunity to improve our understand-
ing of the mechanism behind early-onset CRC. In this regard, we
are currently investigating whether LINE-1 hypomethylation
causes direct transcriptional reactivation of certain proto-onco-
genes in this setting, a unique feature that might help explain the
aggressive clinical behavior of early-onset CRC. In addition, our
results give rise to the hypothesis that the LINE-1 hypomethylation
in peripheral blood could also be evaluated as a prognosis marker
in early-onset CRCs.
Lynch syndrome is the most frequent hereditary cause of CRC,
and accounts for approximately 1–3% of all CRCs [7]. It is an
autosomal dominant condition caused by germline mutations in
the DNA MMR genes (MLH1, MSH2, MSH6, PMS2), and MSH2
and MLH1 account for ,90% of identifiable families. This
syndrome has a gene-dependent variable penetrance for CRC and
endometrial carcinoma, and an increased risk for various other
extracolonic tumors. The diagnosis of Lynch syndrome has been
traditionally based on tumor MMR deficiency analysis when this
disease is suspected [10,11], but the definitive diagnosis is
established by finding a deleterious germline mutation in a DNA
MMR gene. However, detecting Lynch syndrome is a particular
challenge in the absence of a reliable family history. For this
reason, universal screening with tumor MMR-deficiency analysis
has been suggested [34,35]. We have previously shown that MMR
deficiency accounts for up to 20% of early-onset CRC cases [4,5].
We also found that the pattern of MMR deficiency in early-onset
Figure 2. Kaplan–Meier survival curves depicting the effect of LINE-1 methylation on 3-year overall survival in early-onset CRC
patients. Vertical tick marks indicate censored events. The green line represents survival in CRCs with LINE-1 hypomethylation ,65% (n = 92) and the
blue line represents LINE-1 methylation $65% (n = 23). p value for log rank and Fisher’s exact test are shown.
doi:10.1371/journal.pone.0045357.g002
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CRC patients is not identical to that for all Lynch syndrome cases,
and is characterized by in increased frequency of MSH6 and
PMS2 deficiency. Another diagnostic challenge are MSH6-
deficient CRC, as these might be missed if the screening algorithm
relies entirely on MSI testing and does not include MMR
immunohistochemistry [22]. In the present study, we evaluated the
MMR status in an Argentinian population of early-onset CRC by
analyzing both MSI and immunohistochemistry of the four MMR
proteins. Twenty seven (22.9%) tumors were classified as MMR
deficient. MSH2 and MLH1 deficiency accounted for the majority
of cases, however, up to 20% were due to either MSH6 or PMS2
deficiency. One out of 9 MLH1-deficient cases had a BRAF
mutation, which is typically associated with MLH1 promoter
hypermethylation. In the rest of the MLH1-deficient cases, 4 had
different degrees of MLH1 methylation, suggesting that promoter
methylation might be the second hit in putative Lynch syndrome
MLH1-type patients [36,37]. It is noteworthy that 2 patients had
MSI tumors with normal DNA MMR protein expression,
Table 5. Clinical, pathological and molecular features of patients according to the LINE-1 methylation levels.
Clinical, pathological or molecular features LINE-1$65% (n = 23) LINE-1,65% (n = 92) p-value
Sex, n (%)
Male 9 (39.1) 45 (48.9) 0.4
Female 14 (60.9) 47 (51.1)
Mean age (standard deviation)* 37.65 (8.3) 37.36 (8.3) 0.8
Family history of CRC1, n (%)
Yes 4 (17.4) 12 (13) 0.736
No 19 (82.6) 80 (87)
Tumor location, n (%)
Rectum 7 (30.4) 40 (43.5) 0.209
Distal to splenic flexure 6 (26.1) 29 (31.5)
Proximal to splenic flexure 10 (43.5) 23 (25)
Synchronous or metachronous CRC, n (%)
Yes 3 (13) 2 (2.2) 0.054
No 20 (87) 90 (97.)8
TNM tumor stage, n (%)
I–II 9 (39.5) 31 (33.7) 0.625
III–IV 14 (60.9) 61 (66.3)
Tumor differentiation, n (%)
Well or moderate 18 (81.8) 79 (87.8 0.489
Poor 4 (18.2) 11 (12.2)
Mucinous component, n (%)
.50% 14 (60.9) 25 (27.5) 0.003
,50% 9 (39.1) 66 (72.5)
Medullary growth pattern, n (%)
Yes 2 (8.7) 9 (9.9) 1
No 21 (91.3) 82 (90.1)
Crohns reaction, n (%)
Yes 5 (21.7) 7 (8) 0.124
No 18 (78.3) 80 (92)
Tumor infiltrating lymphocytes, n (%)
Yes 5 (21.7) 21 (23.9) 0.83
No 18 (78.3) 67 (76.1)
Microsatellite instability, n (%)
MSI 6 (26.1) 19 (20.7) 0.572
MSS 17 (73.9) 73 (79.3)
Mismatch repair deficiency2, n (%)
Yes 7 (30.4) 20 (21.7) 0.379
No 16 (69.6) 72 (78.3)
*P value was calculated by t-test.
1Including first and second degree relatives.
2MSI-H and/or loss of expression of MMR proteins by immunohistochemistry.
doi:10.1371/journal.pone.0045357.t005
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highlighting possible limitations when using either method, since
these patients would not have otherwise been identified if
immunohistochemistry had been used as the only screening
technique. Our results also revealed that most patients with
MMR-deficient tumors did not display any significant family
history of CRC or other Lynch syndrome associated tumors.
These facts underscore the importance of considering the
diagnosis of Lynch syndrome in all early-onset CRC even in the
absence of family history, given the important clinical implications
for the management of affected individuals and their relatives [38].
We found only 1 case with biallelic germline mutations in the
MUTYH gene (p.Y176C;p.W472S) in a 29-year-old female with
no family history and a MSS rectal cancer. The p.W472S variant
has not been previously described and is predicted to be probably
damaging based on PolyPhen 2 software analysis [39]. Therefore,
novel and previously unrecognized MUTYH mutations should also
be considered when evaluating early-onset CRC.
In spite of all the strengths, there are potential limitations of this
study. First of all, comparison between groups from different
geographical areas can potentially induce a selection bias.
However, we were able to find a unique molecular feature in
two clinical and pathologically similar cohorts of early-onset CRC
from different countries, and far from a limitation, we think that
this actually constitutes one of the strengths of our investigation.
The differences between LINE-1 methylation in the two cohorts of
early-onset CRC patients remains unexplained in this article and
actually gives rise to interesting hypothesis regarding tumor
biology or environmental factors influencing LINE-1 methylation.
Secondly, multivariate overall survival analysis was not performed
because of the limited number of patients. Larger studies are
needed in the future to further confirm the association between
CRC DNA hypomethylation and poorer outcomes, specifically in
the early-onset patients. Also, information about chemotherapy
was not available and accordingly we could not analyze the
predictive value of LINE-1. On the other hand, germline MMR
genetic testing was not done in patients with MMR deficiency to
confirm Lynch syndrome; for MLH1-deficient cases, we ruled out
CIMP-associated tumors by analyzing the V600E BRAF mutation
and MLH1 methylation status. Since somatic inactivation of
MSH2, MSH6, and PMS2 are rare events, we hypothesized that
most patients with MMR deficiency in this study are putative
Lynch syndrome cases. Finally, we only studied the 2 most
prevalent MUTYH mutations in Caucasian population, which
account for .85% of cases. Despite the fact that in Argentina
.75% of the population are European descendants, our results
may be underestimated due to the presence of mutations other
than G393D or Y176C.
In summary, we have studied a large cohort of early-onset CRC
cases and found that LINE-1 hypomethylation in these tumors
constitutes a unique and specific feature compared with older-
onset CRC, which is suggestive of a distinct molecular subtype of
these colorectal neoplasms. Our results suggest that the LINE-1
methylation status could be used as prognostic biomarker for
young people with CRC. Future studies are needed to confirm this
association and to understand the mechanisms by which DNA
hypomethylation affects CRC prognosis, as well as to examine
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